Antiretroviral treatment for HIV infection: Swedish recommendations 2019

• The Swedish Reference Group for Antiviral Therapy (RAV) published recommendations for the treatment of HIV infection in this journal most recently in 2017. An expert group under the guidance of RAV here provides updated recommendations. The most important updates in the present guidelines are the following: (a) The risk of HIV transmission through condomless sex from individuals with fully suppressed HIV viral load is effectively zero. (b) Pre-exposure prophylaxis (PrEP) is recommended for groups with a high risk of HIV infection. (c) Since the last update, two new substances have been registered: bictegravir and doravirine. (d) Dual treatment may be an alternative in selected patients, using lamivudine + dolutegravir or lamivudine + boosted darunavir/atazanavir. As with previous publications, recommendations are evidence-graded in accordance with the Oxford Centre for Evidence Based Medicine. This document does not cover treatment of opportunistic infections and tumours.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Infektionsmedicin (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Infectious Medicine (hsv//eng)

Nyckelord

Antiretroviral

HIV

treatment guidelines

Sweden

adult

paediatric

tenofovir disoproxil fumarate

cervical intraepithelial neoplasia

human-papillomavirus vaccine

randomized double-blind

once-daily

dolutegravir

public-health agency

short-term risk

initial treatment

hiv-1-infected patients

drug-resistance

Infectious Diseases

Publikations- och innehållstyp

ref (ämneskategori)

art (ämneskategori)